An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcutaneous Sonelokimab in Adolescents With Moderate to Severe Hidradenitis Suppurativa (VELA-TEEN)

Phase 3 Active not recruiting 35 enrolled MoonLake Immunotherapeutics AG

NaSingle-groupOpen-labelTreatment

This is a study to evaluate the pharmacokinetic (PK) and safety of sonelokimab in adolescent patients with HS.

Evaluation	Drug	Modality	Dose	Route
Subject	M1095	Protein / enzyme biologic	120 mg	Subcutaneous